Jeff Albers

Jeff Albers is a seasoned executive in the biopharmaceutical industry with extensive experience in leadership roles. Currently serving as a Venture Partner at Atlas Venture since January 2023, Albers also holds multiple board leadership positions, including Board Chair at Antares Therapeutics, Spyre Therapeutics, and Pheon Therapeutics, as well as Chairman at Triveni Bio and MOMA Therapeutics. Albers has been a Board Member at Kymera Therapeutics since July 2020 and held the role of Executive Chair at Scorpion Therapeutics from January 2024 to March 2025. Previously, Albers was Chairman and Chief Executive Officer at Blueprint Medicines, leading the company from June 2014 to July 2025. Albers's earlier role as President, US at Algeta ASA focused on the commercial launch of a significant treatment for prostate cancer. Albers holds an MBA from Georgetown University McDonough School of Business, a JD from Georgetown University Law Center, and a BS in Marketing from Indiana University Bloomington.